top of page
230803_aboutus_web_low.jpg

About Us

Centenaire Biosciences was founded to bring new hope to patients with incurable disease in the homo-hundred era. We are developing next-generation therapeutic antibodies to address high unmet needs in key therapeutic areas including oncology.

Our proprietary Twin Fc-ICE technology harnesses the power of avidity to potentiate a wide range of antibody-dependent immune responses. This platform stands apart from conventional Fc engineering technologies, providing a unique opportunity to tackle the limited efficacy of traditional antibodies in disease treatment.

We focus on authenticity, upholding the highest standards of ethics and integrity, and ensuring that every aspect of its operations aligns with its core values.

btn_1.png
btn_2.png
btn_3.png

About Company

Centenaire Biosciences, Inc.

2021. 05. 03

Date of establishment

CEO

Gi-Hyeok Yang, Ph. D.

Our Values

Aim High, Act Hard, Aid Humanity.

Our Vision

Invent innovative technology, do good science, produce life-saving medicines.

History

history_icon_4.png
history_icon_5.png
history_icon_3.png
history_icon_2.png
history_icon_1-2.png

2021. 05

Discovery of the Star: Establishment

2021. 10

Setting Up the Journey: Patent Application

2022. 03

Building Up the Spaceship: Series-A Funding

2023. 02

Fueling the Spaceship: Additional Funding

2023. 04

Getting into Space: Relocation & Expansion

Leadership

Gi-Hyeok Yang, Ph. D. Chief Executive Officer

Gi-Hyeok Yang is the CEO of Centenaire Biosciences and founded the company in 2021. Previously, Dr. Yang was Chief Technology Officer of Medytox, Inc. which is one of the mid-sized biopharmaceutical companies in South Korea. He led a lot of bio-pharmaceutical R&D projects at Medytox Inc. since he joined the company in 2001. In addition, he had served as a member of Medytox's board of directors since 2001. He received his Ph. D. from Korea Advanced Institute of Science and Technology (KAIST) in 1997 and served as a post-doc at Michigan State University from 1998 to 1999. He also was a post-doc in the antibody engineering lab at Korea Research Institute of Bioscience and Biotechnology (KRIBB) from 1999 to 2001.

Eun Shik Choi, Ph.D., Chief Technology Officer

Eun Shik Choi is the CTO of Centenaire Biosciences and co-founded the company in 2021. Previously, Dr. Choi was a principal scientist at Medytox, Inc. He led the Protein Therapeutics Department at Medytox Inc. since joining the company in 2018. He received his Ph.D. from Seoul National University in 2003 and served as a post-doc at the Wellcome Trust Centre for Cell Biology, U.K., from 2006 to 2011.

Deokjae Lee, Ph.D., Director, Head of Pharmacology Team

Deokjae Lee currently serves as the Director and Head of the pharmacology team. Previously, he held positions as the leader of the Protein Therapeutics team and the manager of the Biologics Development Department at Medytox. Additionally, he served as the Senior Director of the Bioscience Division at Pin Therapeutics in Korea. Throughout these roles, he led pharmaceutical R&D projects focusing on both biologics and small molecules. He obtained his Ph.D. from Seoul National University in 2006 and pursued post-doctoral research at Inha University in Korea and the National Institute of Health in the USA. During these periods, he gained extensive experience in diverse areas such as cell signal transduction, cancer biology, immunology, genomic instability, and epigenetics.

bottom of page